Exploring Complication Risks and Innovations in Postweight Loss Recovery of Emerging Anti-obesity Medications.

IF 2.9 3区医学 Q1 SURGERY

Obesity Surgery Pub Date : 2024-09-10 DOI:10.1007/s11695-024-07496-8

Azhagu Madhavan Sivalingam,Arjun Pandian,Rajajeyakumar Manivel

引用次数: 0

查看原文本刊更多论文

探索新兴抗肥胖药物减肥后恢复的并发症风险和创新。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity Surgery 医学-外科

CiteScore

5.80

自引率

24.10%

发文量

567

审稿时长

3-6 weeks

期刊介绍： Obesity Surgery is the official journal of the International Federation for the Surgery of Obesity and metabolic disorders (IFSO). A journal for bariatric/metabolic surgeons, Obesity Surgery provides an international, interdisciplinary forum for communicating the latest research, surgical and laparoscopic techniques, for treatment of massive obesity and metabolic disorders. Topics covered include original research, clinical reports, current status, guidelines, historical notes, invited commentaries, letters to the editor, medicolegal issues, meeting abstracts, modern surgery/technical innovations, new concepts, reviews, scholarly presentations and opinions. Obesity Surgery benefits surgeons performing obesity/metabolic surgery, general surgeons and surgical residents, endoscopists, anesthetists, support staff, nurses, dietitians, psychiatrists, psychologists, plastic surgeons, internists including endocrinologists and diabetologists, nutritional scientists, and those dealing with eating disorders.

文献相关原料

公司名称	产品信息	采购帮参考价格